Patients
Open a record to continue, or start a new patient.
| Patient | Age / Sex | Latest LDL-C | Record | Risk | Next step | Reimbursement | |
|---|---|---|---|---|---|---|---|
|
Thomas Keller
DEMO-1
Demo
|
58 / Male | 3.8 mmol/L 28.08.2026 | Complete | High | Initiate high-intensity statin | Not applicable | Open Edit |
|
Marc Favre
DEMO-2
Demo
|
64 / Male | 2.1 mmol/L 22.08.2026 | Complete | Very High | Add ezetimibe to the current statin therapy | Not applicable | Open Edit |
|
Claire Rochat
DEMO-3
Demo
|
67 / Female | 2.3 mmol/L 30.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Sophie Berger
DEMO-4
Demo
|
55 / Female | 3 mmol/L 25.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Daniel Huber
DEMO-5
Demo
|
62 / Male | 2.1 mmol/L 19.08.2026 | Complete | High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Not eligible | Open Edit |
|
Muhammad Junaid
PT-0006
|
4 / Male | 0.6 mmol/L 03.09.2026 | Complete | High | At target — continue current therapy and monitor | Not applicable | Open Edit |
|
Muhammad Junaid
PT-0007
|
0 / Male | 0.5 mmol/L 03.09.2026 | Complete | Very High | At target — continue current therapy and monitor | Not applicable | Open Edit |
|
junaid khan
PT-0008
|
0 / Male | 0.5 mmol/L 02.09.2026 | Complete | Very High | At target — continue current therapy and monitor | Not applicable | Open Edit |
Demo patients are synthetic and can be edited freely — use “Reset demo values” inside a record to restore them.